Search - tctmd.com

Displaying 1 - 20 of 149

Sort: Relevancy | Date

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

News Daily News

Year in Review: DCBs Big in Coronary News, Along With Beta-blockers in STEMI

Yael L. Maxwell

December 29, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

News Conference News ESC 2025

AQUATIC: More Than 6 Months After PCI, Don’t Use Aspirin With OAC

September 01, 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

News Conference News ESC 2025

Mixed Results for Beta-blockers in Post-MI Patients With Preserved EF

Michael O'Riordan

August 30, 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

News Conference News EuroPCR 2025

Complete Revascularization in STEMI Still Superior at 10 Years: DANAMI-3-PRIMULTI

Michael O'Riordan

May 20, 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

News Conference News CX Symposium 2025

Paclitaxel or Sirolimus: New PAD Studies Shed Light on Choices

April 23, 2025

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

News Daily News

REVIVED/STICHES Analysis Questions Surgery’s Benefit in Ischemic HF

Michael O'Riordan

March 11, 2025

Top Endovascular News of 2024

News Daily News

Top Endovascular News of 2024

December 28, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

News Conference News TCT 2024

SIRONA: Sirolimus and Paclitaxel DCBs Offer Similar Patency, Function in PAD

October 29, 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

News Conference News TCT 2024

Protecting Coronary Access After TAVI: Valve Choice Clues From CAVEAT

Michael O'Riordan

October 27, 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

News Conference News ESC 2024

‘Unlocking’ Scaffold Matches DES in Wide Range of PCI Patients, Including ACS

Michael O'Riordan

September 09, 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

News Conference News ESC 2024

Complete Revascularization Better for Older STEMI Patients: Meta-analysis

September 04, 2024

FDA Approves Bioresorbable Scaffold for BTK Lesions

News Daily News

FDA Approves Bioresorbable Scaffold for BTK Lesions

Michael O'Riordan

April 29, 2024

To Close Equity Gaps With New PCI-Capable Hospitals, Location Matters

News Daily News

To Close Equity Gaps With New PCI-Capable Hospitals, Location Matters

Michael O'Riordan

December 18, 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

News Conference News TCT 2023

Sirolimus- and Paclitaxel-Coated Balloons Well-Matched for In-Stent Restenosis

November 02, 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

News Conference News EACTS 2023

Surgeons Support Proposed Changes to Left Main CAD Guidelines

Michael O'Riordan

October 13, 2023

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

News Daily News

‘Functional’ SYNTAX Score May Hone PCI, CABG Choices in Multivessel Disease

Michael O'Riordan

September 13, 2023

Surgeons Say ACC/AHA Chronic Coronary Disease Guidelines Whiffed

News Daily News

Surgeons Say ACC/AHA Chronic Coronary Disease Guidelines Whiffed

Michael O'Riordan

August 03, 2023

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.